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5.1 Pharmacovigilance 
Pharmacovigilance is the part of pharmacology that relates to the detection, assessment, 
understanding, and prevention of adverse drug effects and adverse drug interactions.  Initially 
we will consider adverse drug effects and their monitoring, then discuss pharmacodynamic 
and pharmacokinetic examples of adverse drug interactions, and finally discuss therapeutic 
drug monitoring.  It is not possible to discuss all the adverse drug effects or adverse drug 
interactions.  This chapter is just an introduction to pharmacovigilance.  A good source of 
information about adverse drug effects and adverse drug interactions is the Australian 
Medicines Handbook, and an alternative is MIMS.  When adverse drug effects or adverse 
drug interactions have been identified, the ideal solution (if possible), is to avoid the drug or 
drug combination. 
 
 5.1.1 Adverse drug effects 
Adverse drug effects are also known as adverse drug reactions, or side effects of drugs.  The 
World Health Organization (WHO) definition for this is “a response to a drug that is noxious 
and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or 
therapy of disease, or for modification of physiological function”.  This means that for the 
same plasma concentrations, both beneficial and adverse effects may be observed. 
 
  5.1.1.1 Types 
Adverse drug effects have been classified as 3 types; A, B, and C.  A is for Augmentation.  
These side effects are extensions of the drug actions.  This can be because the same binding 
site underlies beneficial and adverse effects of the drug.  For instance, digoxin is used to 
increase the force of the heart beat in people with heart failure.  Digoxin is a Na
+
K
+
-ATPase 
inhibitor.  Inhibition of the cardiac Na
+
K
+
-ATPase produces both the beneficial effect 
(increased heart force) and adverse effects (cardiac arrhythmias) of digoxin on the heart.  In 
addition, Na
+
K
+
-ATPase is present in all cells.  Inhibition by digoxin of Na
+
K
+
-ATPase in 
non-cardiac cells for can cause other adverse effects, such as blurred vision and visual 
disturbances. 
 
Another example of Type A adverse effects is when drugs that show limited selectivity for a 
binding site cause a beneficial action at their target binding site but an adverse effect at 
another binding site.  For example, atenolol is a selective β1-adrenoceptor antagonist that has 
a beneficial effect (antihypertensive) by blocking the cardiac β1-adrenoceptor to decrease 
heart rate and force.  However, as atenolol is only selective, not specific, for β1-
adrenoceptors, this means that atenolol will also have some effect at β2-adrenoceptors.  β2-
adrenoceptors mediate bronchodilation and some metabolism relating to glucose.  The β2-
adrenoceptor blocking action of atenolol is such that it is contraindicated (not to be used) in 
asthmatics. 
 
In type B adverse effects, the B is for Bizarre or idiosyncratic, adverse effects.  For these 
adverse effects, we do not know what the exact mechanism is.  Type B adverse effects 
include allergy.  As drugs are foreign to the body, it is not surprising that allergic reactions to 
drugs are common.  Drug allergy occurs when the body forms antibodies to a particular 
drug, causing an immune response when the person is re-exposed to a drug.  Thus, the 
allergic response is small on first exposure, but can be large on subsequent exposure.  The 
reason for asking new patients “Are you allergic to any drugs?” is to avoid major allergic 
responses.  People who are allergic to the penicillins develop a rash on first exposure. In 
addition, on repeated exposure, people allergic to penicillin develop angioedema (marked 
swelling of the lips, tongue, and face) and anaphylaxis (respiratory distress, hypotension, 
unconsciousness). 
 
In type C adverse effects, the C is for Continuous.   These adverse effects are a consequence 
of continuous (long term) use of drug.  An example is with the continuous use of some of the 
older drugs for schizophrenia, such as haloperidol.  Schizophrenia is an ongoing condition 
requiring continuous medication.  However, the long term use of haloperidol can lead to 
tardive dyskinesia.  Tardive dyskinesia is uncontrollable lip smacking, tongue darting, 
constant chewing movements, and tics.  Some people also have jerky, uncontrolled 
movements of arms and legs. 
 
  5.1.1.2 Monitoring of adverse effects 
The adverse effects of drugs are monitored throughout clinical development, in Phase I, II, 
and III clinical trials.  Phase IV of clinical trialling is post-marketing surveillance.  The 
Therapeutic Goods Administration (TGA) regulates Australia’s medicines, medical devices, 
blood, tissues, and chemicals.  In addition, the TGA has an Adverse Drug Reactions 
Advisory Committee (ADRAC), which is responsible for monitoring the adverse effects of 
drugs when they are widely available (Phase IV post-marketing surveillance).  ADRAC relies 
on anecdotal reporting; Mrs Smith took drug A and developed a rash, i.e where there is no 
direct evidence of a link, and the finding could be coincidental.   However, if lots of reports 
come in that drug A causes a rash, the evidence begins to mount.  ADRAC relies on receiving 
voluntary reports from health professionals, which they monitor.  If they think that the 
evidence linking a drug to an adverse effect is substantial, ADRAC may ask for intensive 
adverse event monitoring for that particular drug.  ADRAC reports its findings in the 
Australian Adverse Drug Reactions Bulletin. 
 
As a health professional, how do you tell whether a reaction is an adverse reaction of a drug?  
There are two general questions to ask the patient.  First, does the reaction get worse with 
increasing doses of the drug?  Most adverse effects of drugs are dose related – the more you 
take, the worse it gets.  If this is the case, it indicates an adverse effect.  Secondly, does the 
reaction go away when the drug is stopped?  Many adverse effects are reversible on removing 
the drug.  If this is the case, it also indicates an adverse effect of the drug. 
 
 5.1.2 Adverse drug interactions 
The second part of Pharmacovigilance is adverse drug interactions.  These can be between a 
prescription drug and a prescription drug or between a prescription drug and a 
complementary or alternative drug.  There are numerous drug interactions, and many of these 
are listed in the Australian Medicines Handbook.  These interactions can be 
pharmacodynamic or pharmacokinetic, and examples of each of these follow. 
 
  5.1.2.1 Pharmacodynamic interactions 
An example of a pharmacodynamic interaction is considered.  Atherosclerosis is usually the 
underlying cause of angina (coronary artery disease) and erectile dysfunction.  Men who 
develop atherosclerosis often have angina and erectile dysfunction.  Nitroglycerin is used to 
relieve or prevent attacks of angina.  Sildenafil (Viagra) is used to treat erectile dysfunction.  
Nitroglycerin acts by mimicking endogenous nitric oxide to stimulate the enzyme guanylate 
cyclase to convert GTP to cGMP, which after a few more steps leads to vasodilation to 
relieve the angina (Figure 5.1).  There is only a small decrease in blood pressure with 
nitroglycerin.   
 
Figure 5.1 Pharmacodynamic drug interaction (Copyright QUT, Sheila Doggrell) 
 Normally, erectile function is mediated by endogenous nitric oxide that stimulates the 
guanylate cyclase to increase the levels of cGMP in the corpus carvenosum, which produces 
relaxation, and blood rushes in to cause penile erection.  The effects of cGMP are short-lived 
as it is rapidly inactivated by the enzyme phosphodiesterase V.  When men take nitroglycerin 
for angina and sildenafil for erectile dysfunction, the sildenafil will inhibit phosphodiesterase 
V in the corpus carvenosum and blood vessels to increase the effect of nitroglycerin (Figure 
5.1).  Thus, the effects of nitroglycerin are increased, and there is a large decrease in blood 
pressure with postural hypotension (dizziness and fainting when standing up).  As a result of 
this interaction, sildenafil is contraindicated in men taking nitroglycerin. 
 
5.1.2.2 Pharmacokinetic interactions 
The enzyme CYP3A4 metabolises 50% of all drugs, and this is source of many drug 
interactions.  The anti-fungal drug ketoconazole inhibits CYP3A4, and this increases plasma 
levels of drugs metabolised by CYP3A4, of which there are many.  For instance, sildenafil 
(Viagra) is metabolised by CYP3A4.  The combination of ketoconazole and sildenafil leads 
to increased levels of sildenafil.  Lower doses of sildenafil are used in men taking 
ketoconazole  
 
 
5.1.3 Therapeutic drug monitoring 
It is obvious that it will be expensive to monitor the levels of drugs by taking blood samples, 
and detecting the levels of drugs in them.  Therapeutic drug monitoring is usually not needed 
if the toxic levels are above the therapeutic concentrations. However therapeutic drug 
monitoring may be needed if toxic levels are similar or overlap therapeutic concentrations.   
 
In practice, therapeutic drug monitoring is required for a number of drugs including the anti-
epileptic, phenytoin.  Therapeutic drug monitoring is used early in treatment with phenytoin 
to find dose that gives therapeutic effect.  Phenytoin is being given to prevent seizures.  If a 
seizure occurs, it may indicate the concentration of phenytoin in the plasma is below the 
therapeutic dose.  Thus, therapeutic drug monitoring of phenytoin commonly occurs after a 
seizure.  Finally, the levels of phenytoin are measured after a change of dose.  
 
Another use of therapeutic drug monitoring is in poisoning to determine the treatment 
required, and this occurs with paracetamol overdose.  If levels are above a certain standard, 
treatment of the overdosage is needed to prevent liver toxicity.  This treatment is discussed in 
eChapter 6.  
 
 
 
 
  
5.2 Introduction to pharmacogenetics 
Pharmacogenetics, or pharmacogenomics as it is also known, is the study of the genetic basis 
for variation in drug response.  These genetic variations are often due to polymorphism, 
which is a variation in the DNA sequence that is present at a frequency of 1% or greater in a 
population.  Polymorphisms differ within human populations e.g. Caucasians, Chinese. These 
polymorphisms can be in enzymes, receptors, ion channels etc, and some examples are 
discussed below. For most polymorphisms, functional information is not available, as the 
study of pharmacogenetics is its infancy.  The ultimate goal of pharmacogenetics is to 
individualise drug treatments on the basis of individual genetics.   
 
 5.2.1 Enzymes 
The example of a polymorphism in an enzyme is with CYP2D6.  About 15-25% of all drugs 
are substrates for this enzyme.   For instance, haloperidol is metabolised by CYP2D6.  With 
polymorphisms of CYP2D6 gene, 5-10% of people have slow metabolism of these drugs.  
The people who are slow metabolisers are likely to have higher plasma levels of drugs 
metabolised by CYP2D6, and more likely to have toxic effects.  Thus, toxicity to haloperidol 
(e.g. tardive dyskinesia) is likely to be more common in slow metabolisers. 
 
With some forms of the polymorphism, the people do not metabolise the drugs normally 
metabolised by this enzyme.  For instance, the conversion of codeine to morphine, which is 
responsible for the analgesic effect of codeine, requires CYP2D6.  Polymorphism in CYP2D6 
leads to 10% of Caucasians not being able to convert codeine to morphine.  In these 10%, 
there is a lack of efficacy of codeine, i.e. it does not have a sufficient analgesic effect. 
 
 5.2.2 Receptors 
Polymorphisms are not always associated with loss of activity.  This is shown in the example 
of the receptor polymorphism; epidermal growth factor receptors.  Epidermal growth 
factor receptors (EGFR) are from the receptor tyrosine kinase (TK) family.  EGFR are 
overexpressed in many cancers, and promote the growth of the cancer.  Gefitinib inhibits 
EGFR-tyrosine kinase, and is used in the treatment of some cancers.  There is a subset of 
patients who respond very well (and much better than most patients) to gefitinib.  This subset 
of patients has a polymorphism in their EGFR-tyrosine kinase.  Gefitinib is a more potent 
inhibitor of the polymorphism than the wild-type (normal) EGFR-tyrosine kinase.  Thus, 
there is a better response to gefitinib in patients with this polymorphism. 
 
 5.2.3 Ion channels 
An example of an ion channel polymorphism is the HERG channel, a potassium channel on 
the heart.  On the electrocardiogram (ECG), QT is a measure of ventricular repolarisation 
(relaxation of heart prior to new beat).  The “Long QT syndrome” is associated prolonged 
relaxation of the heart, such that the heart may not be fully relaxed and ready to beat again.  
This leads to syncope (temporary loss of consciousness and posture) and cardiac 
arrhythmia/sudden death.  This polymorphism is in a particular cardiac potassium channel: 
the HERG channel and can lead to sudden death in young people.  In addition, several drugs 
have been shown to prolong the QT interval by blocking the HERG, and this leads to an 
increased risk of cardiac arrhythmias and sudden death.  Several commonly used drugs have 
been withdrawn, as they have been shown to prolong the QT interval, e.g. some commonly 
used antihistamines were withdrawn after they had been on the market for several years.  To 
make sure this does not happen again, in drug development, it is now mandatory to test 
whether a new drug is an inhibitor of HERG channels. 
 
